The combination of metformin and liraglutide is more effective than metformin monotherapy in improving hyperandrogenism and reproductive abnormalities.44 A meta-analysis showed that liraglutide has the strongest weight loss effect in PCOS patients compared to metformin, inositol, oseltamide, etc,45 and 510% weight loss can improve the menstrual cycle and ovulation recovery in PCOS patients.46,47 Besides, GLP-1RA can improve cardiovascular disease markers such as adiponectin in the treatment of PCOS patients, thus playing a protective role in cardiovascular disease and benefiting PCOS.30 Currently, clinical trials of GLP-1RA in PCOS are based on weight loss effects.33,34,48,49 Consistent with these results, in this study, PCOS mice showed significant weight loss after semaglutide treatment
Available: Accessed March 4, 2025
However, it remains unclear whether lowering Lp(a) levels translates into fewer heart attacks and strokes and large-scale clinical trials are underway to answer that question
faces one of the worlds highest obesity burdens, with 40.3% of adults classified as obese between 2021 and 2023, which is the leading cause of diabetes and increases the market demand
May cause significant IGF-1 elevation in research models monitor levels periodically
Rev Endocr Metab Disord